Esperion Therapeutis.Inc. buy Heureka
Summary
This prediction ended on 10.02.20 with a price of €60.54. The prediction had a final performance of 15.67%. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -26.389% | -26.389% | 59.394% | -89.907% |
iShares Core DAX® | 1.080% | -2.933% | 12.885% | 14.247% |
iShares Nasdaq 100 | 0.362% | 7.015% | 36.826% | 57.151% |
iShares Nikkei 225® | -1.155% | -1.155% | 5.073% | 3.799% |
iShares S&P 500 | 0.806% | 4.388% | 30.269% | 49.772% |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.02.20
09.03.20
09.03.20